The aim of the current study was to develop and validate modular bioPROTACs targeting essential viral proteins. We constructed the degraders by fusing target-specific nanobodies to the BTB domain of SPOP. More importantly, a combination of bioPROTACs targeting different stages of viral replication, delivered via mRNA-LNPs, suppressed viral replication in a pig model. These findings offer valuable insights into the target degradation mechanisms of SPOP-derived bioPROTACs and provide a foundation for the design of antivirals that have activity against multi-lineages of porcine arterivirus and overcome drug resistance.
Su et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: